The Use of Proton Pump Inhibitors in Intensive Care Units

1. Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002; 30(6 ): S373-8.10.1097/00003246-200206001-0000812072665 Search in Google Scholar

2. Thorsen K, Søreide JA, Kvaløy JT, Glomsaker T, Søreide K. Epidemiology of perforated peptic ulcer: age- and gender-adjusted analysis of incidence and mortality. World J Gastroenterol. 2013; 19(3): 347-54.10.3748/wjg.v19.i3.347355481823372356 Search in Google Scholar

3. Abraham E. Acid suppression in a critical care environment: state of the art and beyond. Crit Care Med. 2002; 30(6 Suppl): S349-50.10.1097/00003246-200206001-0000112072659 Search in Google Scholar

4. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients: Canadian Critical Care Trials Groups. N Engl J Med 1994; 330:397-81.10.1056/NEJM1994021033006018284001 Search in Google Scholar

5. Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002; 30(6 Suppl): S351-5.10.1097/00003246-200206001-0000212072660 Search in Google Scholar

6. Conrad SA. Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med. 2002; 30(6 Suppl): S365-8.10.1097/00003246-200206001-0000612072663 Search in Google Scholar

7. Jaspersen D, Koerner T, Schorr W, et al: Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc. 1995; 41:5–7.10.1016/S0016-5107(95)70267-97698624 Search in Google Scholar

8. Halm U, Halm F, Thein D, et al: Helicobacter pylori infection: A risk factor for upper gastrointestinal bleeding after cardiac surgery? Crit Care Med. 2000; 28:110-13.10.1097/00003246-200001000-0001810667508 Search in Google Scholar

9. Simoens M, Gevers AM, Rutgeerte P: Endoscopic therapy for upper gastrointestinal hemorrhage: A state of the art. Hepatogastroenterology. 1999; 46:737–45. Search in Google Scholar

10. Savides TJ, Jensen DM: Therapeutic endoscopy for nonvariceal gastrointestinal bleeding. Gastroenterol Clin North Am. 2000; 29:465-87.10.1016/S0889-8553(05)70123-010836190 Search in Google Scholar

11. Berenholtz S: Management of upper gastrointestinal hemorrhage. Resident Reporter. 1999; 4:112-18. Search in Google Scholar

12. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38(3):316-321.10.1136/gut.38.3.31613830578675081 Search in Google Scholar

13. Richter-Schrag H-J, Glatz T, Walker C, Fischer A, Thimme R. First-line endoscopic treatment with overthe-scope clips significantly improves the primary failure and rebleeding rates in high-risk gastrointestinal bleeding: A single-center experience with 100 cases. Am J Gastroenterol. 2016;22(41):9162-9171. Search in Google Scholar

14. Mokhtare M, Bozorgi V, Agah S, et al. Comparison of Glasgow-Blatchford score and full Rockall score systems to predict clinical outcomes in patients with upper gastrointestinal bleeding. Clin Exp Gastroenterol. 2016; 9:337-343.10.2147/CEG.S114860509675527826205 Search in Google Scholar

15. Barer D, Ogilvie A, Henry D, et al: Cimetidine and tranexamic acid in the treatment of acute upper gastrointestinal-tract bleeding. N Engl J Med 1983; 308:1571–1575.10.1056/NEJM1983063030826066343868 Search in Google Scholar

16. Walt RP, Cottrell J, Mann SG, et al: Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992; 340:143-47. Search in Google Scholar

17. Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Scand J Gastroenterol. 1997; 32:320-27.10.3109/003655297090076799140153 Search in Google Scholar

18. Lau JY, Sung JJ, Lee KKC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000; 343:10-16.10.1056/NEJM20000803343050110922420 Search in Google Scholar

19. Ganser AL, Forte JG. K+-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochem Biophys Acta. 1973; 307: 169-80.10.1016/0005-2736(73)90035-74351147 Search in Google Scholar

20. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005; 14:411-21.10.1517/13543784.14.4.41115882117 Search in Google Scholar

21. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: The H+, K+- ATPase. Annu Rev Pharmacol Toxicol. 1995; 35:277–305.10.1146/annurev.pa.35.040195.0014257598495 Search in Google Scholar

22. Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005; 59:709-15.10.1111/j.1368-5031.2005.00517.x15924600 Search in Google Scholar

23. Ang TL, Fock KM. Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 2006; 21(Suppl 5): S125-28.10.1111/j.1440-1746.2006.04717.x Search in Google Scholar

24. Vakil N. Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 19:1041-49.10.1111/j.1365-2036.2004.01957.x15142193 Search in Google Scholar

25. Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton pump inhibitors do not affect risk for Clostridium difficile infection in the intensive care unit. Am J Gastroenterol. 2016;111(11):1641-48.10.1038/ajg.2016.343509697027575714 Search in Google Scholar

26. Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Critical Care. 2014;18(6):714.10.1186/s13054-014-0714-7429382625540023 Search in Google Scholar

27. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton Pump Inhibitors and Risk for Recurrent Clostridium Difficile Infection Among Inpatients. Am J Gastroenterol. 2013;108(11):1794-801.10.1038/ajg.2013.333396606024060760 Search in Google Scholar

28. Wurst W, Hartmann M. Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med. 1996; 69:233–243. Search in Google Scholar

29. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005; 108:294–307.10.1016/j.pharmthera.2005.05.00516000224 Search in Google Scholar

30. Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franzén S, Hasselgren G. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5:1385-391.10.1016/j.cgh.2007.08.01417950677 Search in Google Scholar

31. Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550-4.10.1634/theoncologist.2011-0431333683722477728 Search in Google Scholar

32. Harty RF, Ancha HB. Stress ulcer bleeding. Curr Treat Options Gastroenterol. 2006; 9: 157-66.10.1007/s11938-006-0034-316539876 Search in Google Scholar

33. Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse. 2006; 26: 18-28.10.4037/ccn2006.26.1.18 Search in Google Scholar

34. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008; 135: 41-60.10.1053/j.gastro.2008.05.03018549814 Search in Google Scholar

35. Sesler JM. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. AACN Adv Crit Care 2007; 18: 119-26.10.1097/01.AACN.0000269254.39967.8e17473539 Search in Google Scholar

36. Spirt MJ. Stress-related mucosal disease: risk factors and prophylactic therapy. Clin Ther. 2004; 26: 197-213.10.1016/S0149-2918(04)90019-7 Search in Google Scholar

37. Constantin VD, Paun S, Ciofoaia VV, Budu V, Socea B. Multimodal management of upper gastrointestinal bleeding caused by stress gastropathy. J Gastrointestin Liver Dis. 2009; 18(3): 279-84. Search in Google Scholar

38. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010; 139(1): 93-101.10.1053/j.gastro.2010.03.055290264920353792 Search in Google Scholar

39. Morgan D. Intravenous proton pump inhibitors in the critical care setting. Crit Care Med. 2002; 30(6): S369-72.10.1097/00003246-200206001-0000712072664 Search in Google Scholar

40. Balsells E, Filipescu T, Kyaw MH, Wiuff C, Campbell H, Nair H. Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations. J Glob Health. 2016; 6(2): 020410.10.7189/jogh.06.020410514007428028434 Search in Google Scholar